Lead program is a Phase 1-ready EBV vaccine candidate with potential to prevent infectious mononucleosis and the serious long-term conditions associated with EBV infection

先导项目是一款处于第一阶段准备就绪的EBV疫苗候选药物，有可能预防传染性单核细胞增多症以及与EBV感染相关的严重长期病症。

BETHESDA, Md.

贝塞斯达，马里兰州

,

，

May 26, 2026

2026年5月26日

/PRNewswire/ -- Vaccine Company, Inc. (Vaccine Company), a privately held pre-clinical-stage biotechnology company developing next-generation vaccines for infectious diseases, today announced entry into a definitive agreement to be acquired by Lilly.

/PRNewswire/ -- 疫苗公司（Vaccine Company），一家致力于开发下一代传染病疫苗的私营临床前阶段生物技术公司，今天宣布已达成一项最终协议，将被礼来公司（Lilly）收购。

Vaccine Company's proprietary In Vivo Nanoparticle (IVN) technologies are designed to enable the antigen display known to elicit durable immune responses associated with virus-like particle vaccines, while avoiding the manufacturing burden of traditional VLP production. The company is advancing a broad preclinical pipeline spanning multiple viral pathogens; the lead program applies this technology to Epstein-Barr Virus (EBV) with a five-antigen Phase 1-ready candidate.

疫苗公司的专有体内纳米颗粒（IVN）技术旨在实现已知能够引发与病毒样颗粒疫苗相关的持久免疫反应的抗原展示，同时避免了传统病毒样颗粒生产所带来的制造负担。该公司正在推进一个涵盖多种病毒病原体的广泛临床前研发管线；其主要项目将此技术应用于爱泼斯坦-巴尔病毒（EBV），并已开发出一种包含五种抗原、处于第一阶段试验准备状态的候选药物。

Given the growing evidence linking EBV to multiple sclerosis and several malignancies, a prophylactic vaccine could prevent not only acute infectious mononucleosis but also the long-term neurological and oncological consequences that may follow infection..

鉴于越来越多的证据表明EBV与多发性硬化症和多种恶性肿瘤有关，一种预防性疫苗不仅可以预防急性传染性单核细胞增多症，还可以预防感染后可能出现的长期神经和肿瘤后果。

Under the terms of the agreement, Lilly will acquire Vaccine Company, and Vaccine Company equity holders could receive up to $1.55 billion in cash, inclusive of an upfront payment and subsequent payments payable upon the achievement of specified clinical and commercial milestones.

根据协议条款，礼来公司将收购疫苗公司，疫苗公司的股东们最高可获得15.5亿美元的现金，其中包括首付款以及在达成特定临床和商业里程碑后支付的后续款项。

'Our pipeline of programs, coupled with our proprietary In Vivo Nanoparticle (IVN) technologies, have the potential for global impact,' said Susan Silbermann, MBA, MA, Chief Executive Officer of Vaccine Company, 'Together with Lilly, we will be positioned to advance our science, move programs through development, and ultimately deliver vaccines to people around the world.' .

“我们的项目管道与专有的体内纳米粒子（IVN）技术相结合，具有全球影响力潜力，”疫苗公司首席执行官苏珊·西尔伯曼（Susan Silbermann），工商管理硕士（MBA）、文学硕士（MA）表示，“与礼来公司携手，我们将能够推进我们的科学，推动项目通过开发阶段，并最终向全世界的人们提供疫苗。”

'Epstein-Barr virus is among the most prevalent human viruses in the world, yet we do not yet have a vaccine against it. Vaccine Company has built a platform we believe may be capable of changing that,' said Daniel M. Skovronsky, M.D., Ph.D., Lilly's chief scientific and product officer, and president, Lilly Research Laboratories.

“爱泼斯坦-巴尔病毒是世界上最普遍的人类病毒之一，但我们至今还没有针对它的疫苗。疫苗公司已经建立了一个平台，我们相信可能有能力改变这一现状，”礼来公司的首席科学官兼产品官、礼来研究实验室总裁丹尼尔·M. 斯科夫隆斯基医学博士说道。

'The case for prevention extends well beyond infectious mononucleosis itself — evidence now links EBV to multiple sclerosis and several malignancies and interrupting that chain earlier could meaningfully reduce the long-term burden of these diseases.'.

“预防的理由远远超出了传染性单核细胞增多症本身——现有证据将EBV与多发性硬化症和多种恶性肿瘤联系起来，及早打断这一链条可能会显著减轻这些疾病的长期负担。”

The transaction is subject to customary closing conditions, including expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

该交易需符合惯例的交割条件，包括《1976年哈特-斯科特-罗迪诺反垄断改进法》规定的等待期届满。

Lazard is acting as exclusive financial advisor, and Cooley LLP is acting as legal counsel to Vaccine Company.

拉扎德担任独家财务顾问，科利律师事务所担任疫苗公司的法律顾问。

About Vaccine Company

关于疫苗公司

Vaccine Company is a privately held pre-clinical-stage biotechnology company founded to bring next-generation antigen engineering to vaccine science. The company's proprietary In Vivo Nanoparticle (IVN) technologies are designed to combine the strengths of mRNA and virus-like particle approaches to enable durable, multivalent immune responses to challenging viral targets.

疫苗公司是一家私人持有的临床前阶段生物技术公司，致力于将下一代抗原工程技术引入疫苗科学。该公司专有的体内纳米颗粒（IVN）技术旨在结合mRNA和病毒样颗粒方法的优势，以实现对复杂病毒目标的持久、多价免疫反应。

Vaccine Company is advancing a pipeline of preclinical and IND-enabling programs, led by a vaccine candidate for the prevention of infectious mononucleosis caused by Epstein-Barr virus. The company was founded in 2022 by ARCH Venture Partners. Luma Group joined as co-founding investor, with further backing from Pfizer Ventures, Wellcome Trust, Lilly Ventures, and Global Health Investment Corporation. .

疫苗公司正在推进一系列临床前和IND支持项目，其中由一款预防由Epstein-Barr病毒引起的传染性单核细胞增多症的候选疫苗领头。该公司于2022年由ARCH风险合作伙伴创立。Luma集团作为共同创始投资者加入，同时得到了辉瑞风险投资、惠康信托、礼来风险投资和全球健康投资公司的进一步支持。

Contact Information

联系方式

Morgan Warners, FGS Global

摩根·沃纳，FGS环球

[email protected]

电子邮件地址

SOURCE Vaccine Company

来源：疫苗公司

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示